Gapping up
In reaction to strong earnings/guidance: MTRX +2.3%, BV +2.1%
Other news: TRVN +35% (announced positive results from its Phase 2b study of TRV130 in acute postoperative pain, showing that the novel mu-opioid receptor modulator achieved its primary endpoint), DRD +19.7% (still checking), MNOV +1.7% (still checking), WTI +1.4% (to sell all of its interest in its Yellow Rose field in the Permian Basin to Ajax Resources for ~$376 mln),SUNE +0.5% (Point72 Asset Management discloses 5.1% passive stake)
Analyst comments: ALKS +3.2% (upgraded toupgraded to Overweight at Morgan Stanley)
Other news: TRVN +35% (announced positive results from its Phase 2b study of TRV130 in acute postoperative pain, showing that the novel mu-opioid receptor modulator achieved its primary endpoint), DRD +19.7% (still checking), MNOV +1.7% (still checking), WTI +1.4% (to sell all of its interest in its Yellow Rose field in the Permian Basin to Ajax Resources for ~$376 mln),SUNE +0.5% (Point72 Asset Management discloses 5.1% passive stake)
Analyst comments: ALKS +3.2% (upgraded toupgraded to Overweight at Morgan Stanley)